JDD Buzz Series | Topical Nonsteroidal Therapies for Atopic Dermatitis
Topical corticosteroids have been a mainstay of frontline therapy for atopic dermatitis (AD) for more than half a century. Now therapeutic advances are challenging that standard of care. Nonsteroidal topicals -- topical JAK inhibitors, aryl hydrocarbon receptor agonists, and PDE-4 inhibitors -- are expanding pathways of addressing the signs and symptoms of AD.
An article in the March Journal …
Topical corticosteroids have been a mainstay of frontline therapy for atopic dermatitis (AD) for more than half a century. Now therapeutic advances are challenging that standard of care. Nonsteroidal topicals -- topical JAK inhibitors, aryl hydrocarbon receptor agonists, and PDE-4 inhibitors -- are expanding pathways of addressing the signs and symptoms of AD.
An article in the March Journal … Continue reading "JDD Buzz Series | Topical Nonsteroidal Therapies for Atopic Dermatitis"